Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol

The single most important prognostic determinant in childhood acute lymphoblastic leukaemia (ALL) is effective therapy and changes in therapy may influence the significance of other risk factors. The effect of intensified therapy on the importance of currently recognized phenotypic and genotypic determinants of outcome was assessed in 2090 children enrolled on the Medical Research Council United Kingdom acute lymphoblastic leukaemia XI (MRC UKALL XI) protocol. Treatment allocation was not determined by risk factors. Multivariate analysis confirmed the dominant influence on prognosis of age, sex and presenting white cell count (WCC). After allowing for these features, blast karyotype, d 8 marrow blast percentage and remission status at the end of induction therapy were the only remaining significant predictors of outcome. Organomegaly, haemoglobin concentration, French–American–British type, body mass index, presence of central nervous system disease at diagnosis, immunophenotype and presence of TEL/AML1 fusion gene (examined in a subset of 659 patients) either had no significant effect on outcome or were significant only in univariate analysis. Among karyotype abnormalities with an independent influence on prognosis, high hyperdiploidy (> 50 chromosomes) was shown to be favourable, whereas near haploidy (23–29 chromosomes), presence of the Philadelphia chromosome, t(4;11) and abnormalities affecting the short arm of chromosome 9 [abn (9p)] were adverse risk factors. Early responders to therapy, determined by residual marrow infiltration after 8 d of induction therapy, had a good outcome, while the small proportion of patients who did not achieve a complete remission by the end of induction therapy had a poor outcome. A third block of late intensification was shown to improve event‐free survival by 8% at 5 years. The effect of these risk factors was not significantly different between those randomized to the third intensification block and those not randomized to a third block.

[1]  A. Vora,et al.  Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials , 2000, Leukemia.

[2]  F. Behm,et al.  Sex differences in prognosis for children with acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Golub,et al.  Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. , 1998, Blood.

[4]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[5]  G. Gustafsson,et al.  Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non‐high‐risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996 , 1998, Acta paediatrica.

[6]  N. Heerema,et al.  Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies , 1998, Cancer.

[7]  A. Baruchel,et al.  Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables , 1998, British journal of haematology.

[8]  O. Eden,et al.  Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI) , 1998, Leukemia.

[9]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[10]  J. Harbott,et al.  Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials , 1998, Leukemia.

[11]  H. Prentice,et al.  The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties , 1998, Leukemia.

[12]  H. Adams,et al.  TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia , 1998 .

[13]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[14]  N. Heerema,et al.  Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Borkhardt,et al.  Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. , 1997, Blood.

[16]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[17]  S. Richards,et al.  Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X , 1997, British journal of haematology.

[18]  F. Mitelman,et al.  Prognostic impact of bone marrow karyotype in childhood acute lymphoblastic leukaemia: Swedish experiences 1986‐91 , 1997, Acta paediatrica.

[19]  Maria Grazia Valsecchi,et al.  Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials , 1997 .

[20]  S. Richards,et al.  Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin , 1997, British journal of haematology.

[21]  J. Downing,et al.  TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Downing,et al.  Non-Hodgkin's lymphoma in childhood. , 1996, The New England journal of medicine.

[23]  H. Sather,et al.  Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C C Bailey,et al.  Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials * , 1995, British journal of haematology.

[25]  C. C. Bailey,et al.  Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X , 1995, The Lancet.

[26]  B. Horizonte,et al.  Malnutrition as a prognostic factor in lymphoblastic leukaemia: a multivariate analysis. , 1994, Archives of disease in childhood.

[27]  A. Morley,et al.  Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.

[28]  G. Reaman,et al.  Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Behm,et al.  Hyperdiploid (47-50) acute lymphoblastic leukemia in children. , 1992, Blood.

[31]  O. Eden,et al.  Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients , 1992, British journal of haematology.

[32]  F. Behm,et al.  Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. , 1990, Blood.

[33]  H. Sather,et al.  Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Ritter,et al.  Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .

[35]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[36]  P S Gaynon,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Association of Chromosome Arm 9p Abnormalities With Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group , 2016 .

[37]  N. Heerema,et al.  Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. , 1999, Leukemia & lymphoma.

[38]  H. Adams,et al.  TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group. , 1998, Blood.

[39]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Y. Komada,et al.  Improved therapy for children with acute lymphoblastic leukemia. , 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  L. Frankel,et al.  Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. , 1992, Leukemia.

[42]  G. Henze,et al.  Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.

[43]  F. Berthold,et al.  [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. , 1987, Klinische Padiatrie.